Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Not Applicable

Completed

• Conditions: Age-related Macular Degeneration
• Interventions: Drug: Bevacizumab

• Registration Number: NCT01032109
• Lead Sponsor: Kumamoto University

Brief Summary

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10
• Primary Completion: 2008-05
• Study Completion: 2008-05
• Study First Submitted: 2009-12-12
• Study First Submitted QC: 2009-12-14
• Study First Posted: 2009-12-15
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-25
• Last Update Posted: 2016-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• choroidal neovascularization caused by age-related macula degeneration
• no previous treatment
• a follow-up at least 12 months
• a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion Criteria

• choroidal neovascularization caused by other eye diseases
• ocular surgery within the past 3 mouths
• history of uveitis
• intraocular pressure higher than 25 mmHg, or glaucoma
• history of systemic or ocular thromboembolic events.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Bevacizumab	Bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Visual acuity	The comparison between baseline and 12-month

Trial Locations

Locations (1)

Department of Ophthalmology and Visual Science, Graduate School of Medical Sciences, Kumamoto University; 🇯🇵 Kumamoto, Japan